Key Points. In persons of AA, a polygenic risk score in the top 10% (compared with 25%-75%) is associated with an 80% increased multiple myeloma risk.Common ge
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
A 63-year-old man presented with fever, splenomegaly, hyperferritinemia (10 798 ng/dL), elevated soluble interleukin-2R (6644 pg/mL), anemia (hemoglobin 6.9 g/dL), and thrombocytopenia (42 000/μL). Atypical…
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
In this issue of Blood, Gerds et al identified persistent leukocytosis above the upper normal value as a risk factor for thrombosis in polycythemia vera. F
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
